OvaScience’s (OVAS) “Hold” Rating Reaffirmed at Oppenheimer Holdings, Inc.
Several other research analysts have also weighed in on the stock. Credit Suisse Group restated an underperform rating and set a $1.00 price objective on shares of OvaScience in a research note on Tuesday, April 18th. HC Wainwright restated a buy rating and set a $15.00 price objective on shares of OvaScience in a research note on Friday, May 12th. Finally, Zacks Investment Research lowered shares of OvaScience from a buy rating to a hold rating in a research note on Thursday, May 4th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $5.83.
OvaScience (NASDAQ:OVAS) traded down 5.99% during midday trading on Thursday, hitting $1.57. 230,136 shares of the company traded hands. The company’s market capitalization is $56.03 million. OvaScience has a 12-month low of $1.25 and a 12-month high of $8.98. The stock’s 50-day moving average price is $1.52 and its 200 day moving average price is $1.51.
OvaScience (NASDAQ:OVAS) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.02. The company had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. OvaScience had a negative net margin of 16,132.47% and a negative return on equity of 64.49%. OvaScience’s revenue for the quarter was down 55.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.62) EPS. On average, equities analysts forecast that OvaScience will post ($1.60) EPS for the current year.
WARNING: This report was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/06/ovasciences-ovas-hold-rating-reaffirmed-at-oppenheimer-holdings-inc.html.
Several hedge funds have recently made changes to their positions in OVAS. EcoR1 Capital LLC bought a new stake in shares of OvaScience during the first quarter valued at approximately $6,568,000. Legal & General Group Plc increased its stake in shares of OvaScience by 4,654.1% in the second quarter. Legal & General Group Plc now owns 458,822 shares of the biotechnology company’s stock valued at $713,000 after buying an additional 449,171 shares during the last quarter. Sabby Management LLC increased its stake in shares of OvaScience by 774.7% in the first quarter. Sabby Management LLC now owns 423,775 shares of the biotechnology company’s stock valued at $792,000 after buying an additional 375,325 shares during the last quarter. GMT Capital Corp increased its stake in shares of OvaScience by 43.6% in the first quarter. GMT Capital Corp now owns 757,114 shares of the biotechnology company’s stock valued at $1,416,000 after buying an additional 229,719 shares during the last quarter. Finally, KCG Holdings Inc. bought a new stake in shares of OvaScience during the first quarter valued at approximately $375,000. 63.63% of the stock is owned by institutional investors and hedge funds.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.